Flurandrenolide
As of the edition of 20 October 2026, Flurandrenolide is a small molecule: marketed, first approved in 1982 (US); acts on NR3C1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2005
- Kind
- Small molecule
- Brand name
- Cordran
- First approved
- 1 January 1982 (US)
- Approvals on record
- 9 in 2 regions
- Holder of the most recent approval
- BIOLAB SANUS FARMACĂUTICA LTDA; 4 holders in all
- Registered trials
- 2, 1 stopped early
- Disease areas
- Mental health; Nervous system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NR3C1 | Glucocorticoid receptor | P04150 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 2 | 1 | 0 | 0 | 1 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Almirall | Acquired holder | 2019 to now |
| Ina Pharmaceutics | Acquired holder | 2025 to now |
| Eli Lilly | Earlier holder |